Technical meeting
(Antwerp, April 2023)

Assessing the health burden of vaccine-preventable infections
in European Adults: challenges and opportunities

• PFD Meeting agenda overview –  AIB technical meeting
  Programma Adult Immunization Board_ TM1 _April 2023 

         Thursday, 20 April 2023

     SESSION 1: Welcome and meeting definition setting 
     Chairs: Pierre Van Damme and Paolo Bonanni

• Welcome and introduction of Adult Immunization Board / Pierre Van Damme (University of Antwerp) and Paolo Bonanni (University of Florence)
  

• Short intro on what is health burden of disease (focus on VPIs)/ Brecht Devleesschauwer (Lifestyle and chronic diseases, Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium)

• • Adult vaccine space general overview of the current VPIs / Joe Schmitt (University of Cologne, Germany, Global Health Press, Singapore) – Remote

     SESSION 2: The methodology and challenges of computing the health burden of adult VPIs (focus on Europe)

        2.1 Burden of (vaccine-preventable) infectious disease studies
        Chairs: Giovanni Gabutti and Ligita Jancoriene

• BCoDe study: results from the Burden of Communicable Diseases in Europe study (2009-2013) / ECDC toolkit to calculate DALYs and the European Surveillance System (TESSy) / Mirjam Kretzschmar (National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands)

• Burden of infectious disease studies in Europe and the United Kingdom: a review  of methodological design choices / Periklis Charalampous (Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands)

• BVPD study: The burden of vaccine preventable diseases in Australia / Tracy Dixon (Australian Institute of Health and Welfare, Australia) – Remote

• ONBOIDS: Ontario Burden of Infectious Disease Study / Jeffrey C Kwong (ICES, Public Health Ontario, Toronto, Dalla Lana School of Public Health, University of Toronto) – Remote

           2.2 Health information systems and data sources
           Chairs: Robert Steffen and Birgit Weinberger

• WHO Surveillance guidelines: A global comprehensive VPD surveillance strategy for the immunization Agenda 2030s/ Anindya Bose (Department of Immunization, Vaccines & Biologicals (IVB), WHO, Geneva)

• EU Data sources European data sources for computing burden of (potential) VPD in ageing adults (VITAL working group) / Alejandro Orrico Sánchez (Vaccines Research Department (AIV), FISABIO, Valencia)

• Burden of disease studies in the WHO European Region & the European Burden of Disease Network (burden-eu)  / Mark O’Donovan (University College Cork, Cork, Ireland)

• European Health Data Space (EHDS): EU health data collection and data safety: impact on the estimation of burden of VPIs / Dipak Kalra (European Institute for Innovation through Health Data (i~HD), Ghent)

           2.3 What can we learn from the GBD study?
           Chairs: Thomas Weinke and Helena Maltezou

• Lessons from 30 years of large scale GBD study / Tomislav Mestrovic (University of Washington’s Institute for Health Metrics and Evaluation (IHME), Seattle, US)

     SESSION 3: The epidemiology and health burden of selected adult VPIs (Part 1)       
     Chairs: Thomas Weinke and Helena Maltezou

           3.1 Health Burden of VPI in a pandemic situation

• COVID-19 example / Sara Monteiro Pires (European Burden of Disease Network National Food Institute, Technical University of Denmark, Kgs Lyngby, Denmark)

           3.2 Health Burden of VPI in older adults

• Herpes zoster example / Hester E de Melker (National Institute for Public Health and the Environment (RIVM), Utrecht, The Netherlands)

• Herpes zoster example/ Angela Bechini (University of Florence, Italy)
  

• RSV example / Xiao Li (Centre for Health Economics Research & Modelling Infectious Diseases (CHERMID), University of Antwerp, Belgium)

• RSV Influenza example/ Stefania Maggi (National Research Council-NI-Aging Branch, Padua, Italy)

         Friday, 21 April 2023

     SESSION 3: The epidemiology and health burden of selected adult VPIs (Part 2)      
     Chairs: Jacek Wysocki and Daphne Holt

          3.3 Health Burden of VPI in younger adults

• HPV example / Paolo Bonanni (University of Florence)

          3.4 Health Burden of VPIs in travelers

• Vaccine‐Preventable Travel Health Risks What Is the Evidence—What Are the Gaps? / Robert Steffen
  (University of Zurich, Switzerland)

         3.5 Health Burden of VPIs in immunocompromised

• Burden of VPIs in immunocompromised populations – Per Ljungman ((Karolinska University Hospital, Karolinska Comprehensive Cancer Center, Karolinska Institutet, Stockholm, Sweden))

     SESSION 4: From theory to practice:
     how are health burden estimates used to recommend adult vaccines in national immunization programs in Europe
     Chairs: Roman Chlibek and Heini Salo

• Knowledge Translation and Burden of Disease, from theory to practice / Ziad El-Khatib
  (Karolinska Institute, Stockholm, Sweden) – Remote

• The impact of the health burden in an archetype analysis of older adult immunization decision-making and implementation (focus on Europe) / Lois Privor-Dumm (Johns Hopkins Bloomberg School of Public Health, International Vaccine Access Center, Baltimore, United States)

• Impact of the health burden on Vaccine market access pathways in the EU27 and United Kingdom – analysis and recommendations for improvements/ Chiara Cadeddu (Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy)

         Examples of how health burden estimates are used to recommend adult vaccines in NIPs
         Chairs: Aparna Keegan and Odile Launay

• Example NITAG (N-Europe) Finland / Heini Salo (Finnish Institute for Health and Welfare, Finland)

• Example NITAG (C-Europe) Czech Republic / Roman Chlibek (Department of Epidemiology, Vaccination Centre, Faculty of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic)

• Example NITAG (W-Europe) Germany / Thomas Weinke (Klinikum Ernst von Bergmann, Medizinische Klinik, Gastroenterologie, Infektiologie, Pneumologie, Potsdam)

• Example NITAG (S-Europe) Greece / Sotirios Tsiodras (University of Athens Med School 4th Dept of Medicine, Greece)  – Remote

     SESSION 5: Summary of the meeting

• Conclusion of the meeting / Chloé Wyndham-Thomas (P95)
• Discussion and closing of the meeting